Findings

What do systematic reviews say?

3,696 questions · 3,815 findings · 855 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 573 · 15%GRADE not reported 374 · 9.8%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Ulipristal acetate (all doses) vs placebo

Duration of bleeding Total bleeding in 90 days (bleeding calendar)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

Duration of bleeding (menstrual diary)

2 findings from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 110 participants
Low
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 152 participants
Low

Intervention not reported

Percentage days bleeding or spotting (questionnaire)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Low

Intervention not reported

Duration of bleeding Median number of bleed days (diary)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 168 participants
Low

Intervention not reported

Duration of bleeding % spotting and bleeding days

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Very low

Intervention not reported

Duration of bleeding Median number of bleeding and spotting days (diary)

1 finding from 1 review

Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
Very low

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.59 [0.26, 1.31]
4 studies · 3068 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.55 [0.11, 2.77]
1 study · 1245 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.98 [0.2, 4.83]
1 study · 1091 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with artesunate‐amodiaquine (AS‐AQ) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.49 [0.3, 0.81]
1 study · 1257 participants
Moderate
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.98 [0.78, 1.23]
1 study · 1235 participants
Moderate

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1.41 [0.28, 7.09]
1 study · 1317 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.4 [0.08, 2.07]
1 study · 1317 participants
Very low

Pyronaridine‐artesunate (PY‐AS) vs artesunate‐amodiaquine (AS‐AQ)

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.99 [0.06, 15.76]
1 study · 1317 participants
Very low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.37 [0.13, 1.05]
1 study · 1117 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1.8 [0.9, 3.57]
1 study · 1037 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) probably leads to lower total failure: day 28 (unadjusted) compared with mefloquine plus artesunate (MQ + AS) (moderate certainty).

2 findings from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.36 [0.17, 0.78]
1 study · 1120 participants
Moderate
Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.31]
1 study · 1059 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs artemether‐lumefantrine (AL)

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 0.86 [0.49, 1.51]
4 studies · 2575 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 1 [0.25, 3.97]
1 study · 1271 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 7.48 [0.99, 56.45]
1 study · 1271 participants
Low

Pyronaridine‐artesunate (PY‐AS) vs mefloquine plus artesunate (MQ + AS)

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).

1 finding from 1 review

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria 2022 · Cochrane Headline outcomes only
RR 9.49 [0.55, 162.64]
1 study · 1271 participants
Very low